Physician Assistant Program year 2025 Reported 2021–2025 Source: CMS Open Payments, 2026 publication

Brandee Burley

Physician Assistant Geneva, NY Physician Assistant

NPI 1184037244 CMS profile 10862338

821 Pre Emption Rd Ste 300, Geneva, NY 14456

Open in the dashboard

General payments

$4,489

334 records reported · program years 2021–2025

Research payments

$0

Paid to them · None reported · program years 2021–2025

Ownership & investment interest

$0

None reported

Through program year 2025, Brandee Burley of Geneva, NY is reported in the CMS Open Payments database as having received $4,489 across 334 general payments and $0 in research payments paid to them.

No combined total General, research and ownership are kept apart. Each is reported under its own rules, and ownership is not money that moved at all but the value of a stake held. A meal, a clinical trial grant and a shareholding do not add up to anything meaningful, so this site does not add them.

General payments for this record sit in the 91st percentile of Physician Assistant profiles with reported payments. Percentile describes the distribution, not the conduct.

By program year

5 rows
Year Kind Relative to this record's peak year Amount Records
2025 General $349 17
2024 General $704 51
2023 General $1,003 78
2022 General $1,409 106
2021 General $1,025 82

Beside peers

Year by year, beside peers General payments · among profiles paid that year
  • Brandee Burley
  • Physician Assistant median
  • Middle half of Physician Assistant
  • National median

In program year 2025, general payments to Brandee Burley were reported at $349. Among 68,903 Physician Assistant profiles paid that year, the median was $184 and the middle half received between $57 and $620.

Show as a table
Year Brandee Burley Physician Assistant median Middle half National median
2019 $0 $34 $17–$122 $163
2020 $0 $33 $16–$78 $114
2021 $1,025 $132 $37–$438 $132
2022 $1,409 $155 $48–$522 $149
2023 $1,003 $167 $52–$557 $160
2024 $704 $178 $55–$600 $164
2025 $349 $184 $57–$620 $169

Breakdown

Who paid General payments · program years 2021–2025
  1. Salix Pharmaceuticals, a division of Bausch Health US, LLC $1,266 146 payments
  2. AbbVie, Inc. $1,006 69 payments
  3. Janssen Biotech, Inc. $488 29 payments
  4. Takeda Pharmaceuticals U.S.A., Inc. $378 20 payments
  5. Ardelyx, Inc. $213 11 payments
  6. Celgene Corporation $189 11 payments
  7. Regeneron Healthcare Solutions, Inc. $144 6 payments
  8. Gilead Sciences, Inc. $115 6 payments
  9. Phathom Pharmaceuticals, Inc. $106 5 payments
  10. Ferring Pharmaceuticals Inc. $105 6 payments
  11. Other $479 25 payments

Every payment, record by record

What the payments were for General payments · program years 2021–2025
  1. Food and Beverage $4,350 330 payments
  2. Education $139 4 payments
Products named General payments · program years 2021–2025
  1. XIFAXAN $1,767 216 payments
  2. PLENVU $578 75 payments
  3. STELARA $446 27 payments
  4. ENTYVIO $318 16 payments
  5. RINVOQ $316 16 payments
  6. LINZESS $260 23 payments
  7. HUMIRA $229 17 payments
  8. IBSRELA $213 11 payments
  9. CREON $205 17 payments
  10. SKYRIZI $199 11 payments
  11. Other $1,547 90 payments

A payment can name more than one product, so these amounts overlap and do not add up to the general-payment figure.

Prescribing to Medicare patients

Part D · data year 2024 · 38 drugs

Part D claims

3,195

Median for Physician Assistant: 241

Drug cost

$1,445,666

Median for Physician Assistant: $4,110

Branded share of claims

24.4%

Median for Physician Assistant: 19.6%

Drugs this doctor was counted under in Medicare Part D 2024, by drug cost
Drug Type Relative to their largest Claims Drug cost
Stelara Ustekinumab Brand 25 $664,077
Humira(Cf) Pen Adalimumab Brand 20 $333,061
Xifaxan Rifaximin Brand 30 $89,749
Linzess Linaclotide Brand 96 $87,753
Creon Lipase/Protease/Amylase Brand 16 $49,759
Ibsrela Tenapanor Hcl Brand 21 $39,631
Mesalamine Generic 62 $36,403
Dexlansoprazole Dr Dexlansoprazole Brand 41 $16,998
Sod Sulf-Potass Sulf-Mag Sulf Sodium, Potassium,mag Sulfates Brand 239 $14,591
Omeprazole Generic 609 $12,338

The 10 drugs with the highest cost, of 38 counted.

Drug cost is what was paid for the drugs at the pharmacy — by Medicare, the patient and others — and is not money to the prescriber. Medicare Part D only: drugs dispensed to Medicare beneficiaries. A drug with fewer than 11 claims for this prescriber is not published, so a missing drug does not mean zero. The medians are for the 114,276 Part D prescribers listed as Physician Assistant; they describe a distribution and say nothing about conduct.

Billing to Medicare

Part B · data year 2024 · 7 billing codes

Paid by Medicare

$23,540

Medicare's payments for the services billed

Medicare patients

306

Average age 73

Services billed

413

190 women, 116 men among their patients

Share of this provider's Medicare patients with each condition
Condition among their Medicare patients Relative to the most common Share of patients
High blood pressure 75%
Arthritis 42%
Diabetes 39%
Ischemic heart disease 27%
Chronic kidney disease 21%
Depression 21%
Atrial fibrillation 19%
Heart failure 17%

Medicare Part B only: services billed to Medicare. Rows covering fewer than 11 beneficiaries are not published. Only drugs given in the clinic are itemised here; the rest of what this provider billed is in the total above.

Payments and prescribing

First 5 of 17 products · payments 2024

Two separate records. The payments come from Open Payments and the claims from Medicare. They are set side by side because they name the same product; they do not show that a payment affected a prescription.

Products this doctor was paid in connection with in 2024, beside Medicare claims for the same product
Product Paid by Related payments Part D claims Part B services
XIFAXAN
  • Salix Pharmaceuticals, a division of Bausch Health US, LLC $166
$166 30 —
RINVOQ
  • AbbVie, Inc. $59
$59 — —
SKYRIZI
  • AbbVie, Inc. $59
$59 — —
VOQUEZNA
  • Phathom Pharmaceuticals, Inc. $44
$44 — —
LINZESS
  • AbbVie, Inc. $23
  • Ironwood Pharmaceuticals, Inc $17
$40 96 —

A dash means Medicare published no figure for this doctor and product — fewer than 11 claims, or the product is not covered under that part — which is not the same as none. Payments are general payments only; one that names several products is split evenly between them, so an amount is payments related to the product, not money paid for it.

See all 17 in the dashboard with a free account

Records

334 reported

Every payment, record by record

Date, company, amount, what it was for and the product named — filter by year, kind and company, or download as CSV.

Other Physician Assistant in New York

Related records

What this means

U.S. law requires drug and medical device manufacturers to report payments and transfers of value they make to physicians and teaching hospitals. The Centers for Medicare & Medicaid Services publishes that record each year. This page shows what was reported about this person, and nothing else.

An ownership interest is different from the other two. It is not a payment: it is a stake — shares, options, a partnership holding — that a physician or an immediate family member held in a manufacturer during that year. The figure shown is what the stake was reported to be worth.

Research payments frequently pass through a clinician to the institution running a trial, and rarely represent personal income. They should be read differently from general payments.

Provenance

Source: CMS Open Payments · through program year 2025

Data current to program year 2025, from CMS's 2026 publication.

We reproduce what manufacturers reported. We do not verify, edit or correct the underlying records.

A payment record is not evidence of wrongdoing. Financial relationships between industry and medicine are legal, common and often necessary for research. Who Paid My Doc reports what was disclosed; it does not judge it.

Who Paid My Doc is independent and is not affiliated with, endorsed by or sponsored by CMS or any U.S. government agency. It is not a consumer reporting agency and this is not a consumer report; do not use it for decisions covered by the Fair Credit Reporting Act.

How to dispute or correct a record